Last reviewed · How we verify
Antithrombotic agents
Antithrombotic agents work by inhibiting platelet aggregation and preventing blood clots.
Antithrombotic agents work by inhibiting platelet aggregation and preventing blood clots. Used for Atrial fibrillation for stroke prevention, Acute coronary syndrome, Deep vein thrombosis and pulmonary embolism.
At a glance
| Generic name | Antithrombotic agents |
|---|---|
| Sponsor | Bayer |
| Drug class | Antithrombotic agents |
| Target | Platelet aggregation inhibitors (e.g. P2Y12 receptor, Factor Xa) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
They do this by targeting various molecular pathways involved in platelet activation and blood coagulation. This can help prevent conditions such as heart attacks and strokes.
Approved indications
- Atrial fibrillation for stroke prevention
- Acute coronary syndrome
- Deep vein thrombosis and pulmonary embolism
Common side effects
- Gastrointestinal bleeding
- Major bleeding
- Thrombocytopenia
Key clinical trials
- Medical Treatment With or Without Transcatheter Patent Foramen Ovale Closure (NA)
- Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism (PHASE4)
- Neuronavigation-assisted Stereotactic Minimally Invasive Puncture With Tenecteplase for Acute Lobar Intracerebral Hemorrhage (PHASE3)
- ULTRAsound-assisted Catheter-guided Thrombolysis for Intermediate-high Risk Patients With PE (NA)
- Optimizing Reperfusion to Improve Outcomes and Neurologic Function (PHASE2, PHASE3)
- TrIal of Early Minimally Invasive Catheter Evacuation With Thrombolysis in IntraCerebral Hemorrhage (NA)
- Single Center Post-Market Study of Thrombolytic Therapy Using the Versus™ Catheter
- Safety and Efficacy of J147 in Acute Ischemic Stroke (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antithrombotic agents CI brief — competitive landscape report
- Antithrombotic agents updates RSS · CI watch RSS
- Bayer portfolio CI